Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors-Reference-Cited by-同舟云学术

Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors

Published:2021-10 Issue:5 Volume:19 Page:467.e1-467.e11
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Morgans Alicia K.,Renzulli Joseph,Olivier Kara,Shore Neal D.

Funder

Genentech

Pfizer

Sanofi

Astellas Pharma US

Janssen Pharmaceuticals

Amgen

Bayer Fund

Bristol-Myers Squibb

Bayer HealthCare

AstraZeneca

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference125 articles.

1. National Cancer Institute. Surveillance, epidemiology, and end results program: cancer stat facts: prostate cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed: May 16, 2019.

2. Neuroanatomical substrates of age-related cognitive decline;Salthouse;Psychol Bull,2011

3. Association between androgen deprivation therapy and risk of dementia;Nead;JAMA Oncol,2017

4. Biomarkers associated with cognitive impairment in treated cancer patients: potential predisposition and risk factors;Castel;Front Pharmacol,2017

5. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset;Cuypers;Support Care Cancer,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta‐analysis;Cancer;2024-02-02

3. The Multifactorial Model of Cancer-Related Cognitive Impairment;Oncology Nursing Forum;2023-03-01

4. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis;International Journal of Radiation Oncology*Biology*Physics;2023-03

5. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer;Future Oncology;2023-02